Taro-Calcipotriol / Betamethasone Gel · DIN 02525178 · 50 mcg/g & 0.5 mg/g · Top Gel
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Taro-Calcipotriol / Betamethasone Gel · DIN 02525178
Manufacturer: Taro Pharmaceuticals Inc.; listing date 2022-06-30
Health Canada: Marketed since 2022-06-01 · brand TARO-CALCIPOTRIOL / BETAMETHASONE GEL · ATC D05AX52 CALCIPOTRIOL, COMBINATIONS · form Gel · route Topical · ingredients CALCIPOTRIOL (CALCIPOTRIOL MONOHYDRATE) 50 MCG/G, BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.5 MG/G · company Taro pharmaceuticals inc · schedule Prescription
Taro-Calcipotriol / Betamethasone Gel: Formulary list price $1.31 per unit (the source does not state the unit; exact figure $1.3142). What the ministry pays, not the patient.
Ministry pays: $1.3142 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02525178)
Source record
DIN 02525178: Taro-Calcipotriol / Betamethasone Gel
Raw flags: sec3=Y
Item: 840600152; group id 840; item number 2045; lccId None; manufacturer id TAR
Source form: Top Gel; strength: 50mcg/g & 0.5mg/g
Recorded listing: General benefit
Source prices (unrounded): $1.3142; ministry $1.3142
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02525178
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101421
Therapeutic Notes (formulary)
Notes:
For the treatment of moderate to severe scalp psoriasis in patients who have failed first-line topical corticosteroid therapy.
For the treatment of mild to moderate body psoriasis in patients who have failed first-line topical corticosteroid therapy and Dovonex (calcipotriol) therapy.
Interchangeable products
Dovobet Gel · DIN 02319012 · $1.3142
Shortage status: not checked (no credentials)